8-KEarnings & ResultsExhibits & Filings

AMGEN INC 8-K Report, Financial Results (Jan 14, 2008)

Filed January 14, 2008For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K on January 13, 2008, reporting an event on January 8, 2008. The key information for investors relates to an updated earnings per share (EPS) guidance for the full year 2007, provided during their presentation at the JP Morgan Healthcare Conference. Despite facing regulatory and reimbursement challenges impacting their Erythropoiesis Stimulating Agent (ESA) products, Amgen now anticipates its adjusted EPS for 2007 will exceed the previously issued guidance range of $4.13 - $4.23 from October 24, 2007. The company expects the final 2007 adjusted EPS to be near the lower end of their initial guidance of $4.30 - $4.50, issued on January 25, 2007, when excluding stock option expenses and other certain costs. This upward revision in guidance, despite headwinds, suggests a stronger operational performance than initially forecast, which is a positive signal for investors monitoring the company's financial health and its ability to navigate industry challenges.

Key Highlights

  • 1Amgen provided updated 2007 adjusted EPS guidance on January 8, 2008.
  • 2The updated guidance was shared during the JP Morgan Healthcare Conference.
  • 3The company expects 2007 adjusted EPS to be above the previously announced October 2007 guidance range ($4.13 - $4.23).
  • 4The updated guidance is projected to be close to the low end of the January 2007 guidance range ($4.30 - $4.50).
  • 5This revision is stated to be 'adjusted EPS', excluding stock option expense and certain other expenses.
  • 6The company mentioned facing regulatory and reimbursement changes impacting sales of ESA products.
  • 7The 8-K filing includes a press release dated January 8, 2008, as an exhibit.

Frequently Asked Questions

Amgen provided an updated guidance for its full-year 2007 adjusted earnings per share (EPS). The company expects its adjusted EPS to be higher than its previous guidance and closer to the lower end of its initial 2007 guidance range.

Amgen mentioned facing regulatory and reimbursement changes that are affecting the sales of its Erythropoiesis Stimulating Agent (ESA) products. Despite these challenges, the company is raising its adjusted EPS guidance.

Amgen expects its 2007 adjusted EPS to be above the October 24, 2007 guidance of $4.13 - $4.23, and close to the low end of the January 25, 2007 adjusted EPS guidance of $4.30 - $4.50 (excluding certain expenses).

The 'adjusted EPS' indicates that the reported earnings per share figure excludes certain items, specifically stock option expenses and 'certain other expenses'. Investors should refer to the full press release (Exhibit 99.1) for details on what these 'certain other expenses' include to fully understand the company's performance.